NCT06243731 A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
| NCT ID | NCT06243731 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Cytomegalovirus (CMV) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2025-11-03 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis). In this study, already existing data will be collected from the participant's medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants.
Eligibility Criteria
Inclusion Criteria: * Adults more than and equal to (≥) 18 years of age at index date. * Diagnosis of comorbid ESRD or comorbid severe CKD prior to the index date. * If ESRD (including participants on peritoneal dialysis or hemodialysis): participant diagnosed with ESRD confirmed by an estimated glomerular filtration rate (eGFR) less than (\<) 15 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2). * If severe CKD: participant diagnosed with severe CKD confirmed by an eGFR of 15 to \<30 mL/min/1.73m\^2 at index. * Participant has undergone solid organ transplant (SOT) or hematopoietic stem cell transplantation (HSCT) before index date. * Participant was diagnosed with refractory (with or without resistance) CMV during the latest post-transplant period. * Participant initiated treatment with maribavir in routine practice within the eligibility period and received at least 1 dose of maribavir. * Informed consent provided (where required by local regulations) before data collection commences. Exclusion Criteria: There are no exclusion criteria for this study.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06243731 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cytomegalovirus (CMV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06243731 currently recruiting?
Yes, NCT06243731 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06243731 trial being conducted?
This trial is being conducted at Anderlecht, Belgium, Leuven, Belgium, Tallinn, Estonia, Tartu, Estonia and 11 additional locations.
Who is sponsoring the NCT06243731 clinical trial?
NCT06243731 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 10 participants.